Chunyan Wu

Chunyan Wu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Genome Biology
Verified
Journal Article
Open access
PDF file
JCJian Chen
Jian Chen
YTYun Tan
Yun Tan
FSFenghuan Sun
Fenghuan Sun
LHLikun Hou
Likun Hou
CZChi Zhang
Chi Zhang
PZPeng Zhang
Peng Zhang
Background: Malignant transformation and progression of cancer are driven by the co-evolution of cancer cells and their dysregulated tumor microenvironment (TME). Recent studies on immunotherapy demonstrate the efficacy in reverting the anti-tumoral function of T cells, highlighting the therapeutic potential in targeting certain cell types in TME. However, the functions of other immune cell types remain largely unexplored. Results: We conduct a single-cell RNA-seq analysis of cells isolated from tumor tissue samples of non-small cell lung cancer (NSCLC) patients, and identify subtypes of tumor-infiltrated B cells and their diverse functions in the progression of NSCLC. Flow cytometry and immunohistochemistry experiments on two independent cohorts confirm the co-existence of the two major subtypes of B cells, namely the naïve-like and plasma-like B cells. The naïve-like B cells are decreased in advanced NSCLC, and their lower level is associated with poor prognosis. Co-culture of isolated naïve-like B cells from NSCLC patients with two lung cancer cell lines demonstrate that the naïve-like B cells suppress the growth of lung cancer cells by secreting four factors negatively regulating the cell growth. We also demonstrate that the plasma-like B cells inhibit cancer cell growth in the early stage of NSCLC, but promote cell growth in the advanced stage of NSCLC. The roles of the plasma-like B cell produced immunoglobulins, and their interacting proteins in the progression of NSCLC are further validated by proteomics data. Conclusion: Our analysis reveals versatile functions of tumor-infiltrating B cells and their potential clinical implications in NSCLC.

10 January 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LHLikun Hou
Likun Hou
TWTingting Wang
Tingting Wang
DCDonglai Chen
Donglai Chen
YSYunlang She
Yunlang She
JDJiajun Deng
Jiajun Deng
XPXiaojie Pan
Xiaojie Pan

1 July 2018 in Clinical Lung Cancer
Verified
Journal Article
Closed access
YLYiwei Liu
Yiwei Liu
ZDZhengwei Dong
Zhengwei Dong
TJTao Jiang
Tao Jiang
LHLikun Hou
Likun Hou
FWFengying Wu
Fengying Wu
FHFred R. Hirsch
Fred R. Hirsch

16 November 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
QZQiang Zheng
Qiang Zheng
YHYan Huang
Yan Huang
XZXin Zeng
Xin Zeng
XCXiaoyan Chen
Xiaoyan Chen
SSShihong Shao
Shihong Shao
YLYuan Li
Yuan Li

1 September 2018 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
EZErjia Zhu
Erjia Zhu
HXHuikang Xie
Huikang Xie
CDChenyang Dai
Chenyang Dai
LZLiping Zhang
Liping Zhang
YHYan Huang
Yan Huang
CCChang Chen
Chang Chen
Invasive adenocarcinoma intraoperatively misdiagnosed as adenocarcinoma in situ or minimally invasive adenocarcinoma is more likely to undergo potentially insufficient resection. The purpose of our study was to evaluate the diagnostic accuracy of frozen section. We retrospectively reviewed 1,111 lung adenocarcinomas from January to March 2016 to evaluate the diagnostic performance of frozen section. A derivation cohort consisting of 436 cases of adenocarcinoma in situ or minimally invasive adenocarcinoma diagnosed by frozen section in the same period were analyzed to find predictive factors for invasive adenocarcinoma as the final diagnosis. Validation cohorts (first: April to June 2016, second: January to March 2015) were included to confirm the results. The overall concordance rate between frozen section and final diagnosis was 92%. Most frozen section errors were underestimation. The sensitivity of frozen section diagnosis for minimally invasive adenocarcinoma (74%) was significantly lower than others. Intraoperatively measured tumor size was the only independent factor for invasive adenocarcinoma as the final diagnosis ( 1.5 cm: 18%, odds ratio, 5.878; P = 0.001) in the derivation cohort, and was confirmed by validation cohorts. Fifty-nine misdiagnosed invasive adenocarcinomas in the three cohorts consisted of 54 lepidic predominant type, 1 papillary and 4 acinar predominant type. There were no positive N1, N2 node, pleural, lymphatic and vascular invasion cases found. Thirty-seven (37/59, 63%) cases of misdiagnosis were attributed to sampling error, which was the main reason. Our study suggests that adenocarcinoma in situ or minimally invasive adenocarcinoma ≥1 cm by frozen section were more likely to be invasive adenocarcinoma because of sampling error. Frozen section diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma should be considered cautiously for tumors ≥1 cm to avoid potentially insufficient resection.

1 March 2021 in Lung Cancer
Verified
Journal Article
Closed access
FZFei Zhou
Fei Zhou
YHYan Huang
Yan Huang
WCWeijing Cai
Weijing Cai
JLJin Li
Jin Li
CSChunxia Su
Chunxia Su
CZCaicun Zhou
Caicun Zhou